Loading
A phase 1/2 trial of Pembrolizumab, Pegylated liposomal doxorubicin in ovarian cancer, run by TILT Biotherapeutics Ltd., active and no longer recruiting.
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. is a phase 1/2 interventional study registered as NCT05271318 by TILT Biotherapeutics Ltd., with 29 participants planned, started 2022-05-17 and due to reach its primary completion in 2027-03. Interventions recorded: TILT-123, pembrolizumab, pegylated liposomal doxorubicin. Conditions listed: Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma. No results are recorded here; the registry entry is the source.
Shares Pegylated liposomal doxorubicin, Platinum-resistant ovarian cancer, Topoisomerase-I inhibitors (and ADC payloads), Ovarian cancer.
Shares Pegylated liposomal doxorubicin, Platinum-resistant ovarian cancer, Topoisomerase-I inhibitors (and ADC payloads), Ovarian cancer.
Shares Pegylated liposomal doxorubicin, Platinum-resistant ovarian cancer, Ovarian cancer, Pembrolizumab.
Shares Pegylated liposomal doxorubicin, Platinum-resistant ovarian cancer, Topoisomerase-I inhibitors (and ADC payloads), Ovarian cancer.
Shares Pegylated liposomal doxorubicin, Platinum-resistant ovarian cancer, Topoisomerase-I inhibitors (and ADC payloads), Ovarian cancer.
Shares Pegylated liposomal doxorubicin, Platinum-resistant ovarian cancer, Ovarian cancer, Cytotoxic chemotherapy.
Shares Platinum-resistant ovarian cancer, Ovarian cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Platinum-resistant ovarian cancer, Ovarian cancer, Cytotoxic chemotherapy.